Abrilumab
- Generic Name
- Abrilumab
- Drug Type
- Biotech
- CAS Number
- 1342290-43-0
- Unique Ingredient Identifier
- Y9UQ37XT2T
- Background
Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 254
- Registration Number
- NCT01696396
- Locations
- 🇬🇧
Research Site, Torquay, United Kingdom
🇺🇸Hospital, New York, New York, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Phase 1
Completed
- Conditions
- Ulcerative ColitisCrohn's Disease
- Interventions
- Other: Placebo for AMG 181
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT01290042
- Locations
- 🇦🇺
Research Site, Prahran, Victoria, Australia
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 72
- Registration Number
- NCT01164904
- Locations
- 🇳🇿
Research Site, Christchurch, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath